Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09)

BACKGROUND: Luteinising-hormone-releasing-hormone agonists (LHRHa) to treat prostate cancer are associated with long-term toxic effects, including osteoporosis. Use of parenteral oestrogen could avoid the long-term complications associated with LHRHa and the thromboembolic complications associated w...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Langley, Ruth E, Cafferty, Fay H, Alhasso, Abdulla A, Rosen, Stuart D, Sundaram, Subramanian Kanaga, Freeman, Suzanne C, Pollock, Philip, Jinks, Rachel C, Godsland, Ian F, Kockelbergh, Roger, Clarke, Noel W, Kynaston, Howard G, Parmar, Mahesh KB, Abel, Paul D
Médium: Artigo
Jazyk:Inglês
Vydáno: Lancet Pub. Group 2013
Témata:
Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3620898/
https://ncbi.nlm.nih.gov/pubmed/23465742
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(13)70025-1
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky